These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 32950044)

  • 1. Efficacy of convalescent plasma according to blood groups in COVID-19 patients.
    Hacibekiroğlu T; Kalpakçı Y; Genç AC; Hacibekiroğlu İ; Sunu C; Saricaoğlu A; Tomak Y; Karabay O; Köroğlu M
    Turk J Med Sci; 2021 Feb; 51(1):45-48. PubMed ID: 32950044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Convalescent plasma therapy in patients with COVID-19.
    Altuntas F; Ata N; Yigenoglu TN; Bascı S; Dal MS; Korkmaz S; Namdaroglu S; Basturk A; Hacıbekiroglu T; Dogu MH; Berber İ; Dal K; Kınık K; Haznedaroglu İ; Yılmaz FM; Kılıç İ; Demircioğlu S; Yosunkaya A; Erkurt MA; Turgut B; Caglayan M; Celik O
    Transfus Apher Sci; 2021 Feb; 60(1):102955. PubMed ID: 33011076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of correlation between ABO Rh(D) blood group and neutralizing antibody titers in SARS-CoV-2 convalescent plasma donors.
    Hirani R; Hoad V; Gosbell IB; Irving DO
    Transfusion; 2022 Feb; 62(2):292-297. PubMed ID: 34936102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of high titer convalescent anti-SARS-CoV-2 plasma: From donor selection to monitoring recipient outcomes.
    Mendoza RP; Fyke W; Daniel D; Gabutan E; Das B; Bajaj H; Easy M; Vasileva A; Colbourn R; Alawad M; Dehghani A; Lin B; Emechebe D; Patel P; Jabbar A; Nikolov DB; Giovaniello D; Kang S; Tatem L; Bromberg K; Augenbraun M; Premsrirut P; Libien J; Norin AJ
    Hum Immunol; 2021 Apr; 82(4):255-263. PubMed ID: 33640208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thinking more about therapy with convalescent plasma for COVID-19 patients.
    Han G; Zhou YH
    Hum Vaccin Immunother; 2020 Nov; 16(11):2601-2603. PubMed ID: 32643512
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-A and SARS-CoV-2: an intriguing association.
    de Freitas Dutra V; Bonet-Bub C; Yokoyama APH; Achkar R; Machado RRG; Assunção M; Candelária G; Soares CP; Fachini RM; Fontão-Wendel R; Hamerschlak N; Reis LFL; Araujo DB; Nudelman V; Pinho JRR; Rizzo LV; Sakashita AM; Scuracchio P; Durigon EL; Wendel S; Kutner JM
    Vox Sang; 2021 May; 116(5):557-563. PubMed ID: 33650690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of COVID-19 convalescent plasma use in COVID-19 with focus on proof of efficacy.
    Devarasetti PK; Rajasekhar L; Baisya R; Sreejitha KS; Vardhan YK
    Immunol Res; 2021 Feb; 69(1):18-25. PubMed ID: 33492637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
    Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
    JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial.
    Balcells ME; Rojas L; Le Corre N; Martínez-Valdebenito C; Ceballos ME; Ferrés M; Chang M; Vizcaya C; Mondaca S; Huete Á; Castro R; Sarmiento M; Villarroel L; Pizarro A; Ross P; Santander J; Lara B; Ferrada M; Vargas-Salas S; Beltrán-Pavez C; Soto-Rifo R; Valiente-Echeverría F; Caglevic C; Mahave M; Selman C; Gazitúa R; Briones JL; Villarroel-Espindola F; Balmaceda C; Espinoza MA; Pereira J; Nervi B
    PLoS Med; 2021 Mar; 18(3):e1003415. PubMed ID: 33657114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Convalescent Plasma Therapy in the management of COVID-19 patients-The newer dimensions.
    Mahapatra S; Rattan R; Mohanty CBK
    Transfus Clin Biol; 2021 Aug; 28(3):246-253. PubMed ID: 33965621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid-19.
    Liu M; Chen Z; Dai MY; Yang JH; Chen XB; Chen D; You H; Guo X; Leng Y; Yu L; Zhang ML; Wu X; Yang J; Gao C; Tenen DG; Chai L; Ai F
    Transfusion; 2020 Oct; 60(10):2210-2216. PubMed ID: 32770691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study.
    Rojas M; Rodríguez Y; Hernández JC; Díaz-Coronado JC; Vergara JAD; Vélez VP; Mancilla JP; Araujo I; Yepes JT; Ricaurte OB; Pardo-Oviedo JM; Monsalve DM; Acosta-Ampudia Y; Ramírez-Santana C; García PG; Landinez LA; Correales LD; Grass JS; Pérez CR; López GS; Mateus N; Mancera L; Devia RR; Orjuela JE; Parra-Moreno CR; Buitrago AA; Ordoñez IE; Osorio CF; Ballesteros N; Patiño LH; Castañeda S; Muñoz M; Ramírez JD; Bastard P; Gervais A; Bizien L; Casanova JL; Camacho B; Gallo JE; Gómez O; Rojas-Villarraga A; Pérez CE; Manrique R; Mantilla RD; Anaya JM
    BMC Infect Dis; 2022 Jun; 22(1):575. PubMed ID: 35761219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects on mortality of early vs late administration of convalescent plasma in the treatment of Covid-19.
    Kocayiğit H; Demir G; Karacan A; Süner KÖ; Tomak Y; Yaylacı S; Dheir H; Kalpakci Y; Erdem AF
    Transfus Apher Sci; 2021 Aug; 60(4):103148. PubMed ID: 33962885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood group O convalescent plasma donations have significantly lower levels of SARS-CoV-2 IgG antibodies compared to blood group A donations.
    Hayes C; Rubenstein W; Gibb D; Klapper E; Tanaka J; Pepkowitz S
    Transfusion; 2021 Aug; 61(8):2245-2249. PubMed ID: 34036595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial.
    Madariaga MLL; Guthmiller JJ; Schrantz S; Jansen MO; Christensen C; Kumar M; Prochaska M; Wool G; Durkin-Celauro A; Oh WH; Trockman L; Vigneswaran J; Keskey R; Shaw DG; Dugan H; Zheng NY; Cobb M; Utset H; Wang J; Stovicek O; Bethel C; Matushek S; Giurcanu M; Beavis KG; di Sabato D; Meltzer D; Ferguson MK; Kress JP; Shanmugarajah K; Matthews JB; Fung JF; Wilson PC; Alverdy JC; Donington JS
    J Intern Med; 2021 Apr; 289(4):559-573. PubMed ID: 33034095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome.
    Diorio C; Anderson EM; McNerney KO; Goodwin EC; Chase JC; Bolton MJ; Arevalo CP; Weirick ME; Gouma S; Vella LA; Henrickson SE; Chiotos K; Fitzgerald JC; Kilbaugh TJ; John ARO; Blatz AM; Lambert MP; Sullivan KE; Tartaglione MR; Zambrano D; Martin M; Lee JH; Young P; Friedman D; Sesok-Pizzini DA; Hensley SE; Behrens EM; Bassiri H; Teachey DT
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28693. PubMed ID: 32885904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of coronavirus disease 19 convalescent plasma donors and donations in the New York metropolitan area.
    Jain S; Garg K; Tran SM; Rask IL; Tarczon M; Nandi V; Kessler DA; Strauss D; Sachais BS; Yazdanbakhsh K; Rehmani S; Luchsinger L; Shi PA
    Transfusion; 2021 Aug; 61(8):2374-2383. PubMed ID: 33904609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial.
    Chowdhury FR; Hoque A; Chowdhury FUH; Amin MR; Rahim A; Rahman MM; Yasmin R; Amin MR; Miah MT; Kalam MA; Rahman MS
    Trials; 2020 Oct; 21(1):883. PubMed ID: 33106167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.